BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 15301726)

  • 21. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
    J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Hsp90 chaperone complex as a novel target for cancer therapy.
    Goetz MP; Toft DO; Ames MM; Erlichman C
    Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geldanamycin and its anti-cancer activities.
    Fukuyo Y; Hunt CR; Horikoshi N
    Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
    Maloney A; Workman P
    Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
    Hanson BE; Vesole DH
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1375-83. PubMed ID: 19642950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
    Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
    Neckers L
    Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
    [No Abstract]   [Full Text] [Related]  

  • 28. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation.
    Niikura Y; Ohta S; Vandenbeldt KJ; Abdulle R; McEwen BF; Kitagawa K
    Oncogene; 2006 Jul; 25(30):4133-46. PubMed ID: 16501598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
    Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
    J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hsp90: the vulnerable chaperone.
    Chiosis G; Vilenchik M; Kim J; Solit D
    Drug Discov Today; 2004 Oct; 9(20):881-8. PubMed ID: 15475321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.
    Waza M; Adachi H; Katsuno M; Minamiyama M; Sang C; Tanaka F; Inukai A; Doyu M; Sobue G
    Nat Med; 2005 Oct; 11(10):1088-95. PubMed ID: 16155577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.
    Sanderson S; Valenti M; Gowan S; Patterson L; Ahmad Z; Workman P; Eccles SA
    Mol Cancer Ther; 2006 Mar; 5(3):522-32. PubMed ID: 16546966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hsp90: how a chaperone becomes a pharmacological target].
    Jacquemin-Sablon A
    Bull Cancer; 2003 Nov; 90(11):935-6. PubMed ID: 14706894
    [No Abstract]   [Full Text] [Related]  

  • 38. Overview: translating Hsp90 biology into Hsp90 drugs.
    Workman P
    Curr Cancer Drug Targets; 2003 Oct; 3(5):297-300. PubMed ID: 14529382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.